HanmiPharm (128940.KS) reported that its fourth quarter net income from continuing operation before income tax increased to 56.0 billion Korean won from 2.1 billion won, prior year. Net income attributable to shareholders of parent company was 49.0 billion won compared to a loss of 5.0 billion won. Operating income increased to 83.3 billion won from 30.5 billion won.
Fourth quarter sales were 432.96 billion won compared to 351.61 billion won, an increase of 23.14% from prior year.
Shares of HanmiPharm are currently trading at 5,41,000 won, up 0.19%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.